The FY 26 T List has arrived!
25 products/product families made the cut to comprise this year’s TNRP. This list will account for an estimated 86% of new revenue and 44% of total revenue making this, once again, a critical ingredient in the recipe for achieving FY26 quota and building future sales growth for Arthrex, agencies, districts, and territories alike. Consistent with previous lists, all the product teams are represented on this new list.
It is very important to note that FY25 TNRP performance was outstanding with the combined revenue achieving 110% of new revenue and 48% of overall sales. Unfortunately, these results didn’t translate to quota achievement for Arthrex and several agencies. This, by no means, signified an ineffective program but it did remind us that the non-TNRP portfolio can’t be neglected in strategic planning. Many of these products are categorized as “legacy” (older and less technologically advanced) or commoditized in nature; however, they still fill a need in the portfolio and cannot be given less attention especially when our competition covets this business.
Included below is a list of the 25 products along with the mapping for each. Here are some important points to note regarding each product group –
-
Upper Extremity – Next Gen Rotator Cuff and Instability Anchor categories of the past two TNRP lists were changed to just FT SpeedBridge Kits and Tensionable Knotless 1.8 FT, two of the largest revenue drivers of these procedures. Cardiothoracic is back on the list this year due to the outstanding performance in FY 25. We are still maintaining the Next Gen Biceps family of products and CuffMend. Because of the significant conversion of Scorpion to HD Needles, HD Needles did not qualify for this year’s list.
-
Knee/Hip – Next Gen Meniscal Repair from FY 25 has been isolated to FiberStitch and SutureLoc given their ongoing significant growth. Like that of HD Needles, the conversion rate of legacy ACL TR to ACL TRII has been impressive and, thus, failed to reach the minimum growth threshold. Quad Tendon ACL, ACL Backup and Knee FiberTak continue to outpace other products and qualify.
-
Foot/Ankle and Trauma – Many changes span the FA&T segment with the re-appearance of Ankle Fracture Plates and Nails and Syndesmotic TR. Of the Kreulock family, Titanium is driving the new revenue so Stainless was dropped this year. Although we are expecting growth in these important product groups, Metal Compression and MIS failed to make the list this year. Next Gen Achilles, Long Bone Trauma, and TTC Nail continue to be runners in the category and remain on the list.
-
Biologics - the only change to this category is the addition of ArthroFlex. The three other groups (Construct Grafts, Cellular, and Bone Repair) continue to be top growers
-
Capital Consumables - i90 keeps grabbing more market share and remains on the list
-
Capital Equipment - Power is now added to compliment the Synergy Systems and Service categories for this segment
-
Arthroplasty - Revers, Revers, and more Revers!
We’re excited about the additions and changes to this year’s list to help Solve the growth and quota goals in FY 26. Other products (Instability Anchors, Knotless SP SwiveLocks, Hand and Wrist, Cartilage Repair, Ankle Instability, DynaNite, Eclipse, and even products that appeared on the FY 25 list but not here) can’t be overlooked and, thus, will account for the remaining 56% of total revenue. Focusing on these products will help us Evolve to market needs, not just our’s.
We look forward to another year of sales success and continuing to find reliable ways to assist in your growth and quota-achieving efforts!